Charles Schwab
STRO icon

Charles Schwab’s Sutro Biopharma STRO Stock Holding History

Charles Schwab’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Buy
49,302
+38,725
+366% +$1.21M ﹤0.01% 2856
2026
Q1 		$263K Buy
+10,577
New +$191K ﹤0.01% 3266
2025
Q2 		– Sell
-19,990
Closed -$130K – 3570
2025
Q1 		$130K Sell
19,990
-5,210
-21% -$82.1K ﹤0.01% 3304
2024
Q4 		$464K Hold
25,200
– – ﹤0.01% 3161
2024
Q3 		$872K Buy
25,200
+3,517
+16% +$138K ﹤0.01% 2958
2024
Q2 		$635K Buy
21,683
+5,595
+35% +$221K ﹤0.01% 3094
2024
Q1 		$909K Hold
16,088
– – ﹤0.01% 2820
2023
Q4 		$690K Hold
16,088
– – ﹤0.01% 2959
2023
Q3 		$558K Hold
16,088
– – ﹤0.01% 3007
2023
Q2 		$748K Buy
16,088
+1,494
+10% +$74.4K ﹤0.01% 2872
2023
Q1 		$674K Buy
14,594
+179
+1% +$11.4K ﹤0.01% 2855
2022
Q4 		$1.16M Buy
14,415
+1,294
+10% +$89.9K ﹤0.01% 2728
2022
Q3 		$729K Buy
13,121
+1,143
+10% +$67.6K ﹤0.01% 2893
2022
Q2 		$625K Buy
11,978
+11
+0.1% +$614 ﹤0.01% 2982
2022
Q1 		$984K Buy
11,967
+1,012
+9% +$96.3K ﹤0.01% 2855
2021
Q4 		$1.63M Buy
10,955
+168
+2% +$30.1K ﹤0.01% 2766
2021
Q3 		$2.04M Buy
10,787
+387
+4% +$73.6K ﹤0.01% 2701
2021
Q2 		$1.93M Buy
10,400
+2,260
+28% +$442K ﹤0.01% 2724
2021
Q1 		$1.85M Buy
8,140
+1,117
+16% +$265K ﹤0.01% 2685
2020
Q4 		$1.52M Buy
7,023
+437
+7% +$72.4K ﹤0.01% 2676
2020
Q3 		$662K Buy
6,586
+1,763
+37% +$167K ﹤0.01% 2802
2020
Q2 		$375K Buy
4,823
+2,564
+114% +$246K ﹤0.01% 2949
2020
Q1 		$231K Hold
2,259
– – ﹤0.01% 2971
2019
Q4 		$249K Hold
2,259
– – ﹤0.01% 3011
2019
Q3 		$206K Hold
2,259
– – ﹤0.01% 3038
2019
Q2 		$258K Buy
2,259
+948
+72% +$104K ﹤0.01% 3053
2019
Q1 		$150K Hold
1,311
– – ﹤0.01% 3061
2018
Q4 		$119K Buy
+1,311
New +$158K ﹤0.01% 3080

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Charles Schwab's STRO Position: Q2 2026 in Review

Charles Schwab increased its Sutro Biopharma (STRO) stake by 366% in Q2 2026, buying an estimated $1.21M and bringing the position to 49,302 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2856.

Charles Schwab first reported a position in STRO in Q4 2018 and has held it in 28 quarters since. The position peaked at $2.04M in Q3 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Charles Schwab held 49,302 shares of Sutro Biopharma worth $1.64M as of Q2 2026.
  • Charles Schwab bought 38,725 Sutro Biopharma shares in Q2 2026, an estimated $1.21M.
  • Sutro Biopharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2856 holding.
  • Charles Schwab first reported a position in Sutro Biopharma in Q4 2018 and has held it in 28 quarters since.
  • Charles Schwab's Sutro Biopharma position peaked at $2.04M in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.